

Maria Grazia Spillantini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6484326/publications.pdf>

Version: 2024-02-01

96
papers

23,431
citations

34493

54
h-index

51423

90
g-index

98
all docs

98
docs citations

98
times ranked

22170
citing authors

#	ARTICLE	IF	CITATIONS
1	Î±-Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.	13.7	7,181
2	A Century of Alzheimer's Disease. Science, 2006, 314, 777-781.	6.0	1,798
3	Filamentous Î±-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neuroscience Letters, 1998, 251, 205-208.	1.0	941
4	100 years of Lewy pathology. Nature Reviews Neurology, 2013, 9, 13-24.	4.9	939
5	Identification of two distinct synucleins from human brain. FEBS Letters, 1994, 345, 27-32.	1.3	922
6	Tau pathology and neurodegeneration. Lancet Neurology, The, 2013, 12, 609-622.	4.9	893
7	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
8	Tau protein pathology in neurodegenerative diseases. Trends in Neurosciences, 1998, 21, 428-433.	4.2	652
9	Abundant Tau Filaments and Nonapoptotic Neurodegeneration in Transgenic Mice Expressing Human P301S Tau Protein. Journal of Neuroscience, 2002, 22, 9340-9351.	1.7	643
10	The Î±-Synucleinopathies: Parkinson's Disease, Dementia with Lewy Bodies, and Multiple System Atrophy. Annals of the New York Academy of Sciences, 2000, 920, 16-27.	1.8	437
11	Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies. Brain Pathology, 1998, 8, 387-402.	2.1	396
12	Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 667-677.	0.9	381
13	Synthetic filaments assembled from C-terminally truncated Î±-synuclein. FEBS Letters, 1998, 436, 309-312.	1.3	373
14	The Synucleinopathies: Twenty Years On. Journal of Parkinson's Disease, 2017, 7, S51-S69.	1.5	350
15	Î±-Synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Letters, 2001, 509, 22-26.	1.3	326
16	Ubiquitination of Î±-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function. Journal of Biological Chemistry, 2003, 278, 44405-44411.	1.6	325
17	Proteasomal degradation of tau protein. Journal of Neurochemistry, 2002, 83, 176-185.	2.1	302
18	Pathological Changes in Dopaminergic Nerve Cells of the Substantia Nigra and Olfactory Bulb in Mice Transgenic for Truncated Human Î±-Synuclein(1-120): Implications for Lewy Body Disorders. Journal of Neuroscience, 2006, 26, 3942-3950.	1.7	302

#	ARTICLE	IF	CITATIONS
19	Tau Mutations Cause Frontotemporal Dementias. <i>Neuron</i> , 1998, 21, 955-958.	3.8	294
20	Filamentous nerve cell inclusions in neurodegenerative diseases. <i>Current Opinion in Neurobiology</i> , 1998, 8, 619-632.	2.0	247
21	SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. <i>Brain</i> , 2010, 133, 2032-2044.	3.7	236
22	Hereditary Frontotemporal Dementia Caused by Tau Gene Mutations. <i>Brain Pathology</i> , 2007, 17, 63-73.	2.1	182
23	Induction of Inflammatory Mediators and Microglial Activation in Mice Transgenic for Mutant Human P301S Tau Protein. <i>American Journal of Pathology</i> , 2004, 165, 1643-1652.	1.9	180
24	Interaction of tau protein with the dynactin complex. <i>EMBO Journal</i> , 2007, 26, 4546-4554.	3.5	171
25	Atypical, non-standard functions of the microtubule associated Tau protein. <i>Acta Neuropathologica Communications</i> , 2017, 5, 91.	2.4	157
26	Propagation of Tau aggregates. <i>Molecular Brain</i> , 2017, 10, 18.	1.3	154
27	<i>Tau</i> Gene Mutation K257T Causes a Tauopathy Similar to Pick's Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2000, 59, 990-1001.	0.9	145
28	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. <i>Annals of Neurology</i> , 2000, 48, 939-943.	2.8	136
29	Pick's disease associated with the novel Tau gene mutation K369I. <i>Annals of Neurology</i> , 2001, 50, 503-513.	2.8	128
30	Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2000, 1502, 110-121.	1.8	127
31	Frontotemporal Dementia: Implications for Understanding Alzheimer Disease. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006254-a006254.	2.9	127
32	Synaptic failure and α -synuclein. <i>Movement Disorders</i> , 2016, 31, 169-177.	2.2	126
33	Living Neurons with Tau Filaments Aberrantly Expose Phosphatidylserine and Are Phagocytosed by Microglia. <i>Cell Reports</i> , 2018, 24, 1939-1948.e4.	2.9	118
34	Early maturation and distinct tau pathology in induced pluripotent stem cell-derived neurons from patients with <i>MAPT</i> mutations. <i>Brain</i> , 2015, 138, 3345-3359.	3.7	116
35	Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies. <i>Brain</i> , 2018, 141, 521-534.	3.7	114
36	Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy. <i>American Journal of Pathology</i> , 2008, 172, 123-131.	1.9	113

#	ARTICLE	IF	CITATIONS
37	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). <i>Annals of Neurology</i> , 2000, 47, 422-429.	2.8	109
38	Tau inclusions in retinal ganglion cells of human P301S tau transgenic mice: Effects on axonal viability. <i>Neurobiology of Aging</i> , 2011, 32, 419-433.	1.5	108
39	Pathogenesis of the Tauopathies. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 425-431.	1.1	107
40	Cell-Mediated Neuroprotection in a Mouse Model of Human Tauopathy. <i>Journal of Neuroscience</i> , 2010, 30, 9973-9983.	1.7	106
41	Assignment of Human τ -Synuclein (SNCA) and τ^2 -Synuclein (SNCB) Genes to Chromosomes 4q21 and 5q35. <i>Genomics</i> , 1995, 27, 379-381.	1.3	105
42	Perineuronal net digestion with chondroitinase restores memory in mice with tau pathology. <i>Experimental Neurology</i> , 2015, 265, 48-58.	2.0	104
43	τ -synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. <i>Journal of Cell Science</i> , 2015, 128, 2231-2243.	1.2	99
44	Anti-amyloid Compounds Inhibit τ -Synuclein Aggregation Induced by Protein Misfolding Cyclic Amplification (PMCA). <i>Journal of Biological Chemistry</i> , 2014, 289, 11897-11905.	1.6	83
45	Astrocytes in mouse models of tauopathies acquire early deficits and lose neurosupportive functions. <i>Acta Neuropathologica Communications</i> , 2017, 5, 89.	2.4	83
46	Neurodegeneration and the ordered assembly of τ -synuclein. <i>Cell and Tissue Research</i> , 2018, 373, 137-148.	1.5	79
47	Depopulation of dense τ -synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. <i>Acta Neuropathologica</i> , 2019, 138, 575-595.	3.9	79
48	Alpha-synuclein dysfunction in Lewy body diseases. <i>Movement Disorders</i> , 2005, 20, S37-S44.	2.2	76
49	Early behavioural markers of disease in P301S tau transgenic mice. <i>Behavioural Brain Research</i> , 2010, 208, 250-257.	1.2	76
50	Presence of Reactive Microglia and Neuroinflammatory Mediators in a Case of Frontotemporal Dementia with P301S Mutation. <i>Neurodegenerative Diseases</i> , 2011, 8, 221-229.	0.8	74
51	Frontotemporal Dementia with Tau Pathology. <i>Neurodegenerative Diseases</i> , 2007, 4, 236-253.	0.8	69
52	Redistribution of DAT/ τ -Synuclein Complexes Visualized by <i>in Situ</i> Proximity Ligation Assay in Transgenic Mice Modelling Early Parkinson's Disease. <i>PLoS ONE</i> , 2011, 6, e27959.	1.1	62
53	Endogenous alpha-synuclein influences the number of dopaminergic neurons in mouse substantia nigra. <i>Experimental Neurology</i> , 2013, 248, 541-545.	2.0	60
54	Microglia become hypofunctional and release metalloproteases and tau seeds when phagocytosing live neurons with P301S tau aggregates. <i>Science Advances</i> , 2021, 7, eabg4980.	4.7	60

#	ARTICLE	IF	CITATIONS
55	From genetics to pathology: tau and "synuclein assemblies in neurodegenerative diseases. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2001, 356, 213-227.	1.8	58
56	Reduced Axonal Transport and Increased Excitotoxic Retinal Ganglion Cell Degeneration in Mice Transgenic for Human Mutant P301S Tau. <i>PLoS ONE</i> , 2012, 7, e34724.	1.1	56
57	Genetic and pathological links between Parkinson's disease and the lysosomal disorder Sanfilippo syndrome. <i>Movement Disorders</i> , 2012, 27, 312-315.	2.2	56
58	Tau-Driven Neuronal and Neurotrophic Dysfunction in a Mouse Model of Early Tauopathy. <i>Journal of Neuroscience</i> , 2016, 36, 2086-2100.	1.7	56
59	<i>Tau</i> Gene Mutations in Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP τ 17): Their Relevance for Understanding the Neurogenerative Process. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 74-83.	1.8	54
60	Living in Promiscuity: The Multiple Partners of Alpha-Synuclein at the Synapse in Physiology and Pathology. <i>International Journal of Molecular Sciences</i> , 2019, 20, 141.	1.8	52
61	Antibody recognizing 4-sulfated chondroitin sulfate proteoglycans restores memory in tauopathy-induced neurodegeneration. <i>Neurobiology of Aging</i> , 2017, 59, 197-209.	1.5	49
62	Association Between Tau H2 Haplotype and Age at Onset in Frontotemporal Dementia. <i>Archives of Neurology</i> , 2005, 62, 1419.	4.9	40
63	A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. <i>Annals of Neurology</i> , 2000, 48, 939-43.	2.8	40
64	Tau and β -Synuclein Inclusions in a Case of Familial Frontotemporal Dementia and Progressive Aphasia. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 245-253.	0.9	39
65	Tau Protein in Frontotemporal Dementia Linked to Chromosome 3 (FTD-3). <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 878-882.	0.9	36
66	Tau Pathology is Present <i>In Vivo</i> and Develops <i>In Vitro</i> in Sensory Neurons from Human P301S Tau Transgenic Mice: A System for Screening Drugs against Tauopathies. <i>Journal of Neuroscience</i> , 2013, 33, 18175-18189.	1.7	36
67	Tau Protein in Familial and Sporadic Diseases. <i>NeuroMolecular Medicine</i> , 2003, 4, 37-48.	1.8	35
68	Evidence for abnormal tau phosphorylation in early aggressive multiple sclerosis. <i>Acta Neuropathologica</i> , 2009, 117, 583-589.	3.9	35
69	The fluorescent pentameric oligothiophene pFTAA identifies filamentous tau in live neurons cultured from adult P301S tau mice. <i>Frontiers in Neuroscience</i> , 2015, 9, 184.	1.4	34
70	Human Stem Cell-Derived Neurons: A System to Study Human Tau Function and Dysfunction. <i>PLoS ONE</i> , 2010, 5, e13947.	1.1	31
71	The microglial P2Y6 receptor mediates neuronal loss and memory deficits in neurodegeneration. <i>Cell Reports</i> , 2021, 37, 110148.	2.9	31
72	Progress in Hereditary Tauopathies: A Mutation in the <i>Tau</i> Gene (G389R) Causes a Pick Disease-like Syndrome. <i>Annals of the New York Academy of Sciences</i> , 2000, 920, 52-62.	1.8	30

#	ARTICLE	IF	CITATIONS
73	Abnormal tau phosphorylation in primary progressive multiple sclerosis. <i>Acta Neuropathologica</i> , 2010, 119, 591-600.	3.9	30
74	Parkinson's disease as a member of Prion-like disorders. <i>Virus Research</i> , 2015, 207, 38-46.	1.1	30
75	Alpha-synuclein modulates NR2B-containing NMDA receptors and decreases their levels after rotenone exposure. <i>Neurochemistry International</i> , 2015, 85-86, 14-23.	1.9	30
76	The novel MAPT mutation K298E: mechanisms of mutant tau toxicity, brain pathology and tau expression in induced fibroblast-derived neurons. <i>Acta Neuropathologica</i> , 2014, 127, 283-295.	3.9	29
77	Super-resolution imaging reveals β -synuclein seeded aggregation in SH-SY5Y cells. <i>Communications Biology</i> , 2021, 4, 613.	2.0	26
78	Safety, tolerability and pharmacokinetics of the oligomer modulator anle138b with exposure levels sufficient for therapeutic efficacy in a murine Parkinson model: A randomised, double-blind, placebo-controlled phase 1a trial. <i>EBioMedicine</i> , 2022, 80, 104021.	2.7	26
79	Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate. <i>Neurobiology of Disease</i> , 2020, 138, 104789.	2.1	19
80	Mutations in the tau gene (MAPT) in FTDP-17: The family with Multiple System Tauopathy with Presenile Dementia (MSTD). <i>Journal of Alzheimer's Disease</i> , 2006, 9, 373-380.	1.2	18
81	Neuronal expression of pathological tau accelerates oligodendrocyte progenitor cell differentiation. <i>Glia</i> , 2016, 64, 457-471.	2.5	16
82	CSP β reduces aggregates and rescues striatal dopamine release in β -synuclein transgenic mice. <i>Brain</i> , 2021, 144, 1661-1669.	3.7	14
83	pFTAA - a high affinity oligothiophene probe that detects filamentous tau in vivo and in cultured neurons. <i>Neural Regeneration Research</i> , 2015, 10, 1746.	1.6	14
84	Non- β -Alzheimer Degenerative Dementias. <i>Brain Pathology</i> , 1998, 8, 295-297.	2.1	13
85	Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2011, 32, 757.e1-757.e11.	1.5	13
86	Progressive tauopathy in P301S tau transgenic mice is associated with a functional deficit of the olfactory system. <i>European Journal of Neuroscience</i> , 2016, 44, 2396-2403.	1.2	12
87	Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype. <i>Molecular Therapy</i> , 2022, 30, 1465-1483.	3.7	9
88	Release of growth factors by neuronal precursor cells as a treatment for diseases with tau pathology. <i>Archives Italiennes De Biologie</i> , 2011, 149, 215-23.	0.1	9
89	Focal expression of adeno-associated viral-mutant tau induces widespread impairment in an APP mouse model. <i>Neurobiology of Aging</i> , 2013, 34, 1355-1368.	1.5	8
90	Tau aggregation and its relation to selected forms of neuronal cell death. <i>Essays in Biochemistry</i> , 2021, 65, 847-857.	2.1	7

#	ARTICLE	IF	CITATIONS
91	A novel mutation at position +12 in the intron following Exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto). , 2000, 47, 422.		6
92	Synucleinopathies and Tauopathies. , 2012, , 829-843.		5
93	Editorial: Tau Pathology in Neurological Disorders. Frontiers in Neurology, 2021, 12, 754669.	1.1	2
94	TAU GENE MUTATIONS IN FRONTOTEMPORAL DEMENTIA AND PARKINSONISM LINKED TO CHROMOSOME 17. , 2003, , .		0
95	The neurobiology of the tauopathies. , 2003, , 245-261.		0
96	Molecular Biology of Lewy Body Formation. Advances in Behavioral Biology, 2002, , 483-489.	0.2	0